Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 6/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 5/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13100637 | 0.88 | GBA1 (0.45) | S1PR1S1PR5S1PR3PTPN1MEN1 | |
| SCHEMBL14497212 | 0.82 | GBA1 (0.52) | S1PR1S1PR5S1PR3PTPN1MEN1 | |
| SCHEMBL13090652 | 0.82 | GBA1 (0.42) | S1PR5GBA1FUCA1 | |
| SCHEMBL14890255 | 0.80 | S1PR5 (0.52) | S1PR1S1PR5S1PR3FUCA1 | |
| SCHEMBL14760297 | 0.80 | S1PR5 (0.52) | S1PR1S1PR5S1PR3FUCA1 | |
| SCHEMBL14760283 | 0.80 | S1PR5 (0.52) | S1PR1S1PR5S1PR3FUCA1 | |
| SCHEMBL13100614 | 0.80 | GBA1 (0.59) | S1PR1S1PR5S1PR3MEN1KMT2A | |
| SCHEMBL456687 | 0.80 | GBA1 (0.59) | S1PR1S1PR5S1PR3MEN1KMT2A | |
| SCHEMBL14388983 | 0.80 | GBA1 (0.59) | S1PR1S1PR5S1PR3MEN1KMT2A | |
| SCHEMBL13100613 | 0.78 | GBA1 (0.44) | S1PR1S1PR5S1PR3PTPN1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2416656-B1 | METHODS FOR PREVENTING AND/OR TREATING LYSOSOMAL STORAGE DISORDERS | AMICUS THERAPEUTICS INC (US) | 2015-12-23 | — | — | EP | disclosed |
| US-8940766-B2 | Methods for preventing and/or treating lysosomal storage disorders | AMICUS THERAPEUTICS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| EP-2416655-B1 | METHODS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | AMICUS THERAPEUTICS INC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-8304429-B2 | Methods for preventing and/or treating degenerative disorders of the central nervous system | AMICUS THERAPEUTICS, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-20100261753-A1 | METHODS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | AMICUS THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| WO-2010118283-A1 | METHODS FOR PREVENTING AND/OR TREATING LYSOSOMAL STORAGE DISORDERS | AMICUS THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010118282-A1 | METHODS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | AMICUS THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100260740-A1 | METHODS FOR PREVENTING AND/OR TREATING LYSOSOMAL STORAGE DISORDERS | AMICUS THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261753-A1 | METHODS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | SNCA, BDNF, PARK7 | S1PR1 141/4885S1PR5 72/4885S1PR3 29/4885 |
| US-20100260740-A1 | METHODS FOR PREVENTING AND/OR TREATING LYSOSOMAL STORAGE DISORDERS | GBA1, GAA, MAN2B1 | S1PR1 297/4885S1PR5 274/4885S1PR3 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.